Cftr Trikafta denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Trikafta — and Why Those Limits Are Appealable

UnitedHealthcare (UHC) applies quantity-limit edits to Trikafta (elexacaftor/tezacaftor/ivacaftor) as part of its specialty-drug management program. These limits typically restrict the days-supply or number of units dispensed per fill or per period. Because Trikafta is taken on a continuous daily schedule as specified in the FDA-approved prescribing label, any quantity limit that prevents a patient from receiving the amount needed for uninterrupted therapy can represent a clinically inappropriate barrier — and that is a strong basis for appeal.

## Why This Denial Happens

Quantity-limit edits are applied automatically at claims adjudication. UHC sets these limits in its published drug policy, and they are triggered by the days-supply or unit count on the prescription rather than by clinical review. Limits that do not align with standard specialty-pharmacy dispensing practices for a chronic CF medication are particularly vulnerable to override on appeal.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law (fully-insured plans), you may file a formal internal appeal. File within the deadline on the denial letter, commonly 180 days. Request that UHC produce its specific quantity-limit policy and the rationale for the limit applied.
• External review (ACA §2719): After the internal appeal is exhausted — or concurrently if urgent — you may request independent external review. The external reviewer is not bound by UHC's formulary policies and applies evidence-based standards.
• Expedited review: If a supply interruption would seriously jeopardize health, request the 72-hour expedited track for both internal and external review.
• Filing window: External review requests are generally due within approximately four months of the final internal denial — confirm the exact date on your notice.

## Documentation to Gather

1. FDA prescribing label — the current label specifying the prescribed dosing regimen, to demonstrate that the requested quantity is consistent with the approved regimen. 2. Prescriber letter — the CF specialist's statement that the prescribed quantity and days-supply are medically necessary for uninterrupted maintenance therapy, referencing the FDA label. 3. Clinical status documentation — chart notes showing disease severity, lung function trajectory, and the clinical consequences of any supply gap. 4. Specialty pharmacy records — documentation from the dispensing pharmacy confirming that the days-supply requested is standard dispensing practice for this medication class. 5. Mutation and diagnosis confirmation — records confirming the CF diagnosis and that the CFTR mutation falls within the FDA-approved indication.

## Criteria-Mapping Structure

Obtain UHC's published quantity-limit policy for Trikafta and the FDA prescribing label. Build a point-by-point response:

| UHC Quantity-Limit Criterion | Evidence Provided | |---|---| | Permitted days-supply or unit count per the policy | Comparison to FDA label dosing schedule | | Medical-necessity exception criteria | Prescriber letter + clinical severity data | | Standard dispensing practice | Specialty pharmacy attestation |

A well-documented quantity-limit appeal that aligns the requested supply with the FDA label and clinical necessity typically succeeds at internal review without requiring external review.